Belantamab mafodotin targets BCMA on the cell surface; after BCMA-mediated internalization, the MMAF payload binds beta‑tubulin to disrupt microtubules causing G2/M arrest and apoptosis. Tubulin expression alone does not cause cells to be targeted or killed.